Day: June 3, 2025

Singapore, June 03, 2025 (GLOBE NEWSWIRE) — YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce the successful completion of the share transfer of YY Circle Thailand on June 1, 2025. This milestone marks a significant step in YY Group’s strategy to expand its presence in Southeast Asia’s dynamic economies. YY Circle Thailand is now officially part of YY Group’s portfolio, providing an enhanced platform to address workforce demands in Thailand’s vibrant casual labor market, valued at approximately THB170 billion (US$5 billion) annually. The completion of the transaction ensures a seamless transition, with Jirapat Haetanurak, the Country Director of YY Circle Thailand, will remain with YY Circle...

WISeKey’s WISeSat Confirms Next Satellite Launch Scheduled for Mid-June from California to Advance Quantum-Safe Space CommunicationsBy 2027, WISeSat.Space aims to establish a large constellation of satellites, incorporating WISeKey cryptographic keys and PQC semiconductor technology from SEALSQ, to ensure robust, quantum-resistant communication capabilities from space. The WISeSat satellite constellation aims to accelerate the deployment of its satellite constellation, scale QKD capabilities, and enable a scalable “Satellite-as-a-Service” business model that integrates decentralized IoT transactions and post-quantum secure communicationsGeneva, Switzerland, June 3, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, via its subsidiaries, WISeSat.Space...

Geneva, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) —To support its strategic roadmap, SEALSQ intends to invest $10 million in WISeSat )1 as a strategic investor in the WISeSat satellite constellation, aiming to accelerate the deployment of its satellite constellation, scale QKD capabilities, and enable a scalable “Satellite-as-a-Service” business model that integrates decentralized IoT transactions and post-quantum secure communications (more information are available here). By 2027, WISeSat.Space aims to establish a large constellation of satellites, incorporating WISeKey cryptographic keys and PQC semiconductor technology from SEALSQ, to ensure robust, quantum-resistant communication capabilities from space.SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and...

DALIAN, China, June 03, 2025 (GLOBE NEWSWIRE) — CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy,” or the “Company”), a leading lithium-ion battery manufacturer and electric energy solution provider in China, today announced the receipt of a significant follow-up order from Livguard, a prominent Indian energy storage solutions provider. Valued at approximately USD 3 million, this order brings the cumulative value of orders from Livguard to USD 7.9 million since the inception of the partnership. Founded in India, Livguard is backed by the 37-year legacy of the esteemed SAR Group and has emerged as a leader in the Indian energy solutions landscape. With a broad portfolio including inverters, batteries, solar energy systems, and automotive power solutions, Livguard is supported by a robust nationwide...

Vilnius, Lithuania, June 03, 2025 (GLOBE NEWSWIRE) — As at the end of May 2025, the net asset value (NAV) of SUTNTIB AB Tewox increased to EUR 46,740,384, compared to the previously determined NAV of EUR 42,086,793 at the end of April 2025. The share price increased to EUR 1.1165, from EUR 1.0053 at the end of April 2025. The pro-forma internal rate of return (IRR) rose to 3.62%, compared to previously announced IRR of 0.18% at the end of April 2025. Contact person for further information: Paulius Nevinskas Manager of the Investment Company paulius.nevinskas@lordslb.lt https://lordslb.lt/tewox_bonds/

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details are as follows: Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001671Presenter: Rekha Chaudhuri, M.D.Session Title: Clinical Trials on Airways DiseasesDate and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST Abstract Title: Improvement in Lung...

VANCOUVER, British Columbia, June 03, 2025 (GLOBE NEWSWIRE) — Canada Energy Partners Inc. (NEX: CE.H) (the “Company”) announces that the TSX-Venture Exchange has approved an extension of its non-brokered private placement until June 26/2025. Please see the original news release announcing the private placement issued on April 11/2025 for more information. On behalf of the Board of Directors of Canada Energy Partners Inc.: Grant HallPresident For more information, please contact: CANADA ENERGY PARTNERS INC.Attention: Grant Hall, President Email: ghall9612@gmail.comDirect Phone: (520) 668 4101 Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains forward-looking...

ASCO: new Sarclisa data support subcutaneous administration with on-body injectorNew data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion Studies used Enable Injections’ enFuse® on-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance...